Catch up on the top radiology content of the past week.
|Articles|July 8, 2001
Syncor subsidiary acquires Radpharm Scientific
An Australian subsidiary of Syncor has acquired Radpharm Scientific, distributor and manufacturer of diagnostic radiopharmaceuticals. Based in Canberra, Radpharm distributes its products to more than 160 nuclear medicine practices in Australia and
Advertisement
An Australian subsidiary of Syncor has acquired Radpharm Scientific, distributor and manufacturer of diagnostic radiopharmaceuticals. Based in Canberra, Radpharm distributes its products to more than 160 nuclear medicine practices in Australia and exports to New Zealand, Singapore, Malaysia, Thailand, and Hong Kong. The acquisition gives Syncor a presence in Canberra along with its existing sites in Sydney, Perth, and Brisbane.
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears First MRI-Derived AI Software for Assessing Breast Cancer Recurrence Risk
2
What a Large Prostate MRI Study Reveals About AI and Unassisted Radiologist Assessment
3
Diagnostic Imaging's Weekly Scan: October 11 — October 17
4
How Photon-Counting CT Helps Us Recognize that Coronary Stenosis is Just One Piece of the Puzzle
5